Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Public ClinicalTrials.gov record NCT04239625. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Study identification
- NCT ID
- NCT04239625
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- ALK-001 Drug
Drug
Eligibility (public fields only)
- Age range
- 8 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2019
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Apr 26, 2025
2019 – 2026
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkeus Site | Phoenix | Arizona | 85020 | — |
| Alkeus Site | Los Angeles | California | 90095 | — |
| Alkeus Site | Aurora | Colorado | 80045 | — |
| Alkeus Site | Gainesville | Florida | 32601 | — |
| Alkeus Site | Indianapolis | Indiana | 46202 | — |
| Alkeus Site | Grand Rapids | Michigan | 49456 | — |
| Alkeus Site | Westbury | New York | 11590 | — |
| Alkeus Site | Silverdale | Washington | 98383 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04239625, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04239625 live on ClinicalTrials.gov.